Key result
The combination of doxorubicin and resveratrol resulted in the lowest 99m Tc-MIBI uptake in breast cancer xenografts and higher antitumor effect, but increased liver and heart toxicity.
Why the study?
Does the combination of doxorubicin and resveratrol affect 99m Tc-MIBI uptake and histopathology in breast cancer xenograft mice?
Does the combination of doxorubicin and resveratrol affect 99m Tc-MIBI uptake and histopathology in breast cancer xenograft mice?
The combination of doxorubicin and resveratrol enhances antitumor effects as measured by 99m Tc-MIBI uptake, but may increase cardiotoxicity and hepatotoxicity in a mouse xenograft model.
May increase cardiotoxicity risk with resveratrol-doxorubicin; hypothesis-generating for antitumor effects, should not yet change practice.
Background and Objective: Doxorubicin (DOX), despite having antitumor properties, also exhibits cardiotoxicity. Resveratrol has antitumor property for breast cancer cells. 99m Tc-MIBI has higher absorption rate in human breast cancer cell line MCF-7. In the present study, the authors intend to investigate the effect of DOX and resveratrol on the absorption of 99m Tc-MIBI in breast cancer cell xenografts in mice. Materials and Methods: Sixteen xenograft models in nude mice were divided into four groups. Group I (S, control) received 2% DMSO in 0.9% saline, group II (D) 2.5 mg/kg DOX, group III (D + R) 20 mg/kg/d resveratrol with 2.5 mg/kg DOX (total dose of 15 mg/kg in six injections), and group IV (R) 20 mg/kg/d resveratrol for 2 weeks. Single-photon emission computed tomography (SPECT) images were taken for the determination of 99m Tc-MIBI absorption. Mice were sacrificed, and the percentage of injected dose per gram (%ID/g) of the heart, liver, tumor, and muscle was measured using a gamma counter. Hematoxylin–eosin staining and Masson's trichrome staining were used for investigation of histopathological changes. Results: The %ID/g of tumor was lowest in group D + R. The severity of tumor necrosis or apoptosis was highest in group D + R, but there is no significant difference in pathological injuries and %ID/g of tumor between the group D + R and group D. In addition to the results of the %ID/g, the severity of pathological injuries to the liver and heart cells in group D + R was higher compared with group D. There is a significant difference in the %ID/g of the liver between the group D + R and group D. SPECT images showed that the lowest amount of %ID/g was observed in the tumor of group D + R. Conclusions: According to the results of pathology, biodistribution study, and imaging, the combination of DOX and resveratrol has shown higher antitumor effect; hence, 99m Tc-MIBI can be used to evaluate their antitumor effect.
No takes yet. Share an insight, caveat, or question.
Hallajian et al. (2018) studied Breast cancer cell xenografts (n=16). Doxorubicin and resveratrol vs. Control, DOX alone, or resveratrol alone was evaluated on Percentage of injected dose per gram (%ID/g) of 99m Tc-MIBI in tumor. The combination of doxorubicin and resveratrol resulted in the lowest 99m Tc-MIBI uptake in breast cancer xenografts and higher antitumor effect, but increased liver and heart toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: